Haemorrhagic effect of enoxaparin, a low molecular weight heparin. Comparison with unfractionated heparin in humans
- PMID: 1333639
- DOI: 10.3109/00365529209000164
Haemorrhagic effect of enoxaparin, a low molecular weight heparin. Comparison with unfractionated heparin in humans
Abstract
The haemorrhagic effects of unfractionated heparin (UFH) and the low molecular weight heparin (LMWH) enoxaparin were investigated and compared in the gastric mucosa (haemorrhage induced by biopsy) and skin (haemorrhage induced by Simplate) of 12 healthy volunteers. Administration of UFH and LMWH (given in a dose of 75 anti-Xa U/kg intravenously) increased median gastric bleeding time (3.5 min) and geometric mean blood loss (11.5 microliters) to 19 min (p = 0.00003) and 54.1 microliters (p = 0.0021) after UFH and to 13 min (p = 0.008) and 29.0 microliters (p = 0.275) after LMWH. Median skin bleeding time (4.25 min) increased to 6.0 min after UFH (p = 0.003) and to 6.75 min after LMWH (p = 0.0008). Mean heparin activity in plasma was 20% higher after LMWH than after UFH. The calculated gastric bleeding time to heparin activity ratio was significantly lower for LMWH than for UFH (p < 0.05).
Similar articles
-
[Low molecular weight heparin versus unfractionated heparin in the treatment of deep venous thrombosis--a meta-analysis].Ugeskr Laeger. 1994 Oct 3;156(40):5844-9. Ugeskr Laeger. 1994. PMID: 7985276 Clinical Trial. Danish.
-
A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.Thromb Haemost. 1996 Feb;75(2):246-50. Thromb Haemost. 1996. PMID: 8815569 Clinical Trial.
-
Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin.Clin Respir J. 2016 Sep;10(5):596-605. doi: 10.1111/crj.12262. Epub 2015 Apr 8. Clin Respir J. 2016. PMID: 25619125
-
Low-molecular-weight heparin vs. unfractionated heparin in percutaneous coronary intervention: a combined analysis.Catheter Cardiovasc Interv. 2005 Jun;65(2):212-21. doi: 10.1002/ccd.20352. Catheter Cardiovasc Interv. 2005. PMID: 15900551 Review.
-
Intravenous low-molecular-weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials.Arch Intern Med. 2007 Dec 10;167(22):2423-30. doi: 10.1001/archinte.167.22.2423. Arch Intern Med. 2007. PMID: 18071163 Review.
Cited by
-
Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease.Drugs. 1995 Mar;49(3):388-410. doi: 10.2165/00003495-199549030-00006. Drugs. 1995. PMID: 7774513 Review.
-
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates.Blood. 2007 May 1;109(9):3733-40. doi: 10.1182/blood-2006-07-035147. Epub 2007 Jan 16. Blood. 2007. PMID: 17227834 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical